The legacy of the blue pill offers a intricate case study for analysts eyeing pharma. While initial sales were explosive, recent patent expiry and the rise of alternative versions have severely affected revenues. https://craigpytt613292.ka-blogs.com/94492909/the-blue-pill-and-the-pharmaceutical-industry-a-risky-stake